News | Published:

Angst about exclusivity: The potential cost of incentivizing makers of generic drugs

Nature Medicine volume 23, pages 11141116 (2017) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & Int. J. Econ. Bus. 18, 177–201 (2011).

  2. 2.

    , , The landscape of US generic prescription drug markets, 2004-2016. (Working paper no. 23640) (National Bureau of Economics, Cambridge, 2017).

  3. 3.

    US Government Accountability Office. Generic Drugs Under Medicare: Part D Generic Drug Prices Declined Overall, but Some Had Extraordinary Price Increases (US GAO, Washington, DC, 2016)

  4. 4.

    & Rev. Econ. Stat. 96, 214–228 (2014).

  5. 5.

    & The effect of generic drug competition on generic drug prices during the Hatch-Waxman 180-day exclusivity period (Working paper no. 317) (FTC Bureau of Economics, Washington DC, 2013).

Download references

Author information

Affiliations

  1. Shraddha Chakradhar is Nature Medicine's associate news editor in Boston.

    • Shraddha Chakradhar
  2. Roxanne Khamsi is Nature Medicine's chief news editor in New York.

    • Roxanne Khamsi

Authors

  1. Search for Shraddha Chakradhar in:

  2. Search for Roxanne Khamsi in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nm1017-1114

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing